UCSD-led team finds leukemia-killing molecule

Dr. Thomas Kipps and researchers at the UC San Diego Moores Cancer Center have found a monoclonal antibody named RG7356 that may be effective in in killing chronic lymphocytic leukemia cells without harming healthy cells.

Read about it HERE

Embryonic Development Protein Active in Cancer Growth

Silencing it impairs tumor growth, making ROR1 a potential therapeutic target

A team of scientists at the University of California, San Diego Moores Cancer Center has identified a novel protein expressed by breast cancer cells – but not normal adult tissues – that could provide a new target for future anti-cancer drugs and treatments… Read the full story from the UCSD Newsroom

Read the study report in PLoS One

Study senior investigator Thomas J. Kipps, MD, PhD, is Evelyn and Edwin Tasch Chair in Cancer Research and professor of medicine in the Division of Hematology-Oncology. He is Interim Director of the UC San Diego Moores Cancer Center, where he co-leads the Hematologic Malignancies Program.

Dr. Kipps is principal investigator of the UC San Diego site in the Cancer Immunotherapy Trials Network, a research network established last year by the National Cancer Institute and headquartered at the Fred Hutchinson Cancer Research Center in Seattle.

Dr. Kipps was named to the National “Top Doctors” List for 2011-2012. In both 2010 and 2011, he was selected for the “San Diego Top Doctors” list.